METHODS	Previously untreated patients with advanced NSCLC were randomized to receive gemcitabine-paclitaxel on a traditional three-weekly schedule ( Arm A ) or a novel weekly schedule ( Arm B ) as follows-Arm A ( three-weekly ) : gemcitabine 1000 mg/m2 infused > 30 min on days 1 and 8 and paclitaxel 200 mg/m2 infused > 3 h on day 1 of a 21-day cycle or Arm B ( weekly ) : gemcitabine 1000 mg/m2 infused > 30 min and paclitaxel 100 mg/m2 infused > 1 h , both administered on days 1 and 8 of a 21-day cycle .\